Protracted Results of Dose-Intensive Therapy using Cyclophosphamide, Carmustine, and Continuous Infusion Etoposide with Autologous Stem Cell Support in Patients with Relapse or Refractory Hodgkin's Disease: A Phase II Study from the North American Marrow Transplant Group

Autor:	L. Pineiro, Stacy A. Goodman, Roger H. Herzig, Linda J. Goldsmith, John P. Greer, R Brown, Joseph P. Lynch, Brian J. Bolwell, Geoffrey P. Herzig, Don A. Stevens, Richard S. Stein, Steven N. Wolff, Robert H. Collins, Joseph W. Fay, Donald R. Fleming
Rok vydání:	1999
Předmět:	Adult Cancer Research medicine.medical_specialty Adolescent Cyclophosphamide medicine.medical_treatment Phases of clinical research Transplantation Autologous Autologous stem-cell transplantation Refractory Recurrence Antineoplastic Combined Chemotherapy Protocols medicine Humans Infusions Intravenous Etoposide Carmustine Chemotherapy Dose-Response Relationship Drug business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Combined Modality Therapy Hodgkin Disease Surgery Treatment Outcome Oncology North America business Chemoradiotherapy medicine.drug
Zdroj:	Leukemia & Lymphoma. 35:91-98
ISSN:	1029-2403 1042-8194
Popis:	To determine the long-term results of high-dose chemotherapy and stem cell support in relapsed or primary refractory Hodgkin disease patients. One hundred and thirty-one patients with relapsed or primary refractory Hodgkin's disease were treated with a dose-intensive therapy protocol consisting of etoposide (2400 mg/m2 continuous intravenous infusion) cyclophosphamide (7200 mg/m2 intravenously), and carmustine (300-600 mg/m2 intravenously) CBVi. All patients had previously failed conventional chemoradiotherapy. Severe toxicities were related to infectious, hepatic, and pulmonary complications. Fatal, regimen-related toxicity was 19%; liver and lung dysfunction, as well as infection, were the most frequent problems. Ninety-one (69%) of the patients achieved a complete response (CR) (95% CI = 59% to 75%) after CBVi and autologous stem cell infusion. With a median follow-up of 5.1 years (range 3.0 to 9.5 years), overall and event-free survival are 44% (95% CI = 33% to 47%) and 38% (95% CI = 28% to 46%) respectively. While univariate analysis did not reveal a statistically significant variable to predict a better response, responsiveness to therapy demonstrated a trend. We conclude that CBVi is an effective therapy for relapsed or refractory Hodgkin's disease, producing long-term, durable remissions.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdbd0c39ff4068d8d8c48b69ff4cc83 https://doi.org/10.3109/10428199909145708 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.